Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 07/22 05:39:37 pm
76.6 EUR   +0.50%
07/22 PROMIS NEUROSCI : Announces Appointment of Dr. Johanne Kaplan as Chi..
07/21 SANOFI : Information concerning the total number of voting rights an..
07/21 JUNIPER PHARMAC : Appoints Alicia Secor President and Chief Executiv..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

ProMIS Neurosciences : Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2016 | 11:06pm CEST

(PRWeb) - ProMIS Neurosciences (ProMIS or the Company), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it has appointed Johanne Kaplan, PhD, to the position of Chief Development Officer. In this new role, reporting to both the Executive Chairman and CEO, Dr. Kaplan will focus on supporting the design and execution of ProMIS development programs and partnering efforts.

We are pleased to welcome Dr. Kaplan as her extensive skill set and experience will add significant value to the ProMIS team and to this important new role, said ProMIS Executive Chairman, Eugene Williams. Dr. Kaplans track record of successfully managing development-stage programs will benefit the Company as we approach the selection of the final lead candidates for development in our Alzheimers disease portfolio. Furthermore, her experience as a senior executive in pharmaceutical industry in-licensing and product acquisition will be integral as we pursue partnering opportunities.

Johanne Kaplan joins ProMIS following 24 years at Genzyme (a Sanofi company), where she held positions of increasing responsibility, culminating in her decade-long tenure as Vice President of Research, most recently directing the multiple sclerosis and immunology research effort.

I am excited to join ProMIS, a dynamic company at the forefront of developing precision medicine treatments for neurodegenerative diseases, particularly Alzheimers disease and ALS, said Kaplan. I look forward to working with the executive and science teams at ProMIS to help the Company achieve its product development and partnering goals.

About Dr. Johanne Kaplan

Johanne Kaplan is a former VP of Research at Genzyme, a Sanofi Company. Over the course of her career at Genzyme, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, cancer immunotherapy and autoimmunity. Most recently, as VP of Neuroimmunology Research, Dr. Kaplan led the Genzyme science teams contribution to the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an Immunotoxicology program. Her work has resulted in more than 60 scientific publications and multiple patents. Dr. Kaplan holds a PhD in Microbiology and Immunology from McGill University in Montreal, Canada, and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York, USA.

About ProMIS Neurosciences, Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimers disease and ALS.

ProMIS Neurosciences proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platformsProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimers disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at: http://www.promisneurosciences.com

Follow us on Twitter Like us on LinkedIn

NATIONAL Equicom Michael Moore: mmoore(at)national(dot)ca Abby Garfunkel: agarfunkel(at)national(dot)ca

or contact

Dr. Elliot Goldstein President and Chief Executive Officer, ProMIS Neurosciences Inc. Tel. 415 341-5783 Elliot.goldstein(at)promisneurosciences(dot)com

(c) All KUNA right are reserved 2016. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07/22 PROMIS NEUROSCIENCES : Announces Appointment of Dr. Johanne Kaplan as Chief Deve..
07/21 SANOFI : Information concerning the total number of voting rights and shares, pr..
07/21 JUNIPER PHARMACEUTICALS : Appoints Alicia Secor President and Chief Executive Of..
07/20 JUNIPER PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regulat..
07/15 SANOFI : Pasteur signs research agreement for Zika vaccine
07/14 MEDIVATION : Enters into Confidentiality Agreements, Including with Sanofi
07/14 SANOFI : Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Pati..
07/14 SANOFI : Patent Issued for Neutralizing Immunogen (NimIV) of Rhinovirus and Its ..
07/14 SANOFI : Army researchers team with Sanofi Pasteur to co-develop a Zika virus va..
07/14 FINDINGS FROM SANOFI PROVIDE NEW INS : Integration into Clinical...
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 MannKind - Afrezza Sales Pacing Below My Bearish Line - Reality May Sting
07/22 Re-Evaluation Of LDL Cholesterol-Level Impacts Could Benefit Amarin's Vascepa
07/22 WALL STREET BREAKFAST : Markets Get First Glimpse Of Post-Brexit Data
07/22 More Zika worries
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
Advertisement
Financials (€)
Sales 2016 37 117 M
EBIT 2016 9 360 M
Net income 2016 5 093 M
Debt 2016 5 594 M
Yield 2016 3,92%
P/E ratio 2016 18,60
P/E ratio 2017 16,10
EV / Sales 2016 2,81x
EV / Sales 2017 2,75x
Capitalization 98 592 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,0 €
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.54%108 205
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results